Arcturus Therapeutics agrees acquisition of AI drug-discovery company myNEO
Arcturus Therapeutics has agreed to acquire Belgian AI drug-discovery company myNEO, expanding its computational capabilities for mRNA medicine design and target identification.
Arcturus has worked with myNEO since 2024 and plans to integrate the company's artificial-intelligence platform into its broader mRNA discovery and development capabilities.
The acquisition is expected to close in October subject to customary conditions and adds specialised AI expertise to Arcturus' genetic-medicines platform.
Field | Content |
Alert Type | Deal |
Companies | Arcturus Therapeutics; myNEO |
Deal Type | Acquisition |
Asset or Company | myNEO |
Technology or Modality | Artificial intelligence; computational drug discovery; mRNA medicines |
Geography | United States; Belgium |
Transaction Status | Definitive acquisition agreement; expected to close in October subject to customary conditions |
What Happened | Arcturus Therapeutics entered a definitive agreement to acquire Belgian AI drug-discovery company myNEO. |
Why It Matters | The acquisition adds artificial-intelligence capabilities that can support target identification and optimisation of mRNA therapeutic design. |
Supporting Context | Arcturus and myNEO have collaborated since 2024, giving the companies an existing working relationship ahead of integration. |
Strategic Rationale | Arcturus can bring computational target discovery and molecular design capabilities in-house to complement its mRNA technology platform. |
Potential Impact | Integration of AI-based discovery could improve candidate selection and accelerate development of future mRNA medicines. |
Key Takeaway | Arcturus is acquiring myNEO to strengthen AI-driven target discovery and mRNA design capabilities. |
What to Watch | Transaction completion, integration of the myNEO platform and future pipeline programmes generated using the combined technologies. |
Primary Source | Arcturus Therapeutics |
Relevant Date | 23 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
コメント